IL252900B - Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide - Google Patents

Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide

Info

Publication number
IL252900B
IL252900B IL252900A IL25290017A IL252900B IL 252900 B IL252900 B IL 252900B IL 252900 A IL252900 A IL 252900A IL 25290017 A IL25290017 A IL 25290017A IL 252900 B IL252900 B IL 252900B
Authority
IL
Israel
Prior art keywords
methycyclohexylamino
butylamino
carboxamide
pyrimidine
tert
Prior art date
Application number
IL252900A
Other languages
English (en)
Hebrew (he)
Other versions
IL252900A0 (en
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of IL252900A0 publication Critical patent/IL252900A0/en
Publication of IL252900B publication Critical patent/IL252900B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL252900A 2014-12-16 2017-06-14 Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide IL252900B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462092537P 2014-12-16 2014-12-16
US201562196044P 2015-07-23 2015-07-23
PCT/US2015/065774 WO2016100310A1 (fr) 2014-12-16 2015-12-15 Formulations de 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-méthylcyclohexylamino)-pyrimidine-5-carboxamide

Publications (2)

Publication Number Publication Date
IL252900A0 IL252900A0 (en) 2017-08-31
IL252900B true IL252900B (en) 2021-10-31

Family

ID=56110500

Family Applications (1)

Application Number Title Priority Date Filing Date
IL252900A IL252900B (en) 2014-12-16 2017-06-14 Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide

Country Status (19)

Country Link
US (3) US9796685B2 (fr)
EP (2) EP3233809B1 (fr)
JP (2) JP6762940B2 (fr)
KR (1) KR102606253B1 (fr)
CN (2) CN112451502B (fr)
AU (2) AU2015362728B2 (fr)
BR (1) BR112017012795A2 (fr)
CA (2) CA3210612A1 (fr)
CL (1) CL2017001545A1 (fr)
CO (1) CO2017006087A2 (fr)
EA (1) EA033530B1 (fr)
EC (1) ECSP17038150A (fr)
ES (2) ES2972295T3 (fr)
IL (1) IL252900B (fr)
MX (2) MX2017007883A (fr)
NZ (1) NZ732793A (fr)
SA (1) SA517381749B1 (fr)
SG (2) SG10202010389TA (fr)
WO (1) WO2016100310A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105001165B (zh) 2011-04-22 2020-06-23 西格诺药品有限公司 取代的二氨基嘧啶其组合物，和用其治疗的方法
NZ715903A (en) * 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
CA3210612A1 (fr) 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Formulations de 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
JP6903577B2 (ja) 2014-12-16 2021-07-14 シグナル ファーマシューティカルズ，エルエルシー 皮膚におけるｃ−Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法
US20180022710A1 (en) 2015-01-29 2018-01-25 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
WO2017019487A1 (fr) 2015-07-24 2017-02-02 Celgene Corporation Procédés de synthèse de chlorhydrate de (1r,2r,5r)-5-amino-2-méthylcyclohexanol et intermédiaires utiles à cet effet
CN108291903B (zh) * 2015-09-30 2020-07-28 国立大学法人东北大学 糖尿病性肾病的判定标志物
AU2019280822A1 (en) * 2018-06-06 2021-01-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
KR20210029989A (ko) 2019-09-09 2021-03-17 김경민 야구경기 데이터 기록 서버 및 야구경기 기록데이터 분석방법
CN112574123B (zh) * 2019-09-30 2024-06-11 武汉朗来科技发展有限公司 Jnk抑制剂、其药物组合物和用途
WO2024097940A1 (fr) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Thérapie de traitement du cancer

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH549339A (de) 1971-05-12 1974-05-31 Ciba Geigy Ag Herbizides mittel.
EP1054004B1 (fr) 1997-12-15 2008-07-16 Astellas Pharma Inc. Nouveaux derives de pyrimidine-5-carboxamide
JP2002523497A (ja) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
PT1184376E (pt) 1999-06-09 2005-04-29 Yamanouchi Pharma Co Ltd Novos derivados heterociclicos de carboxamida
AU5108000A (en) 1999-06-10 2001-01-02 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
CZ2002534A3 (cs) 1999-08-13 2002-07-17 Vertex Pharmaceuticals Incorporated Inhibitory protein-kináz, farmaceutické prostředky, které je obsahují, a jejich pouľití
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003220968A1 (en) 2002-03-28 2003-10-13 Kyowa Hakko Kogyo Co., Ltd. Anti-inflammatory agent
AU2003244098A1 (en) 2002-06-28 2004-01-19 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxa mide derivative
CN103169708B (zh) 2002-07-29 2018-02-02 里格尔药品股份有限公司 用2,4‑嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
AU2003289330A1 (en) 2002-12-13 2004-07-09 Kyowa Hakko Kogyo Co., Ltd. Preventives and/or remedies for central diseases
DE602004022633D1 (de) 2003-01-30 2009-10-01 Boehringer Ingelheim Pharma 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
DK1660458T3 (da) 2003-08-15 2012-05-07 Irm Llc 2, 4-pyrimidindiaminer egnede i behandling af neoplastiske sygdomme, in-flammatoriske lidelser og lidelser i immunsystemet.
CN1871009A (zh) 2003-09-24 2006-11-29 惠氏控股公司 作为抗癌剂的5－芳基嘧啶
EP1749827A4 (fr) 2004-03-30 2010-04-21 Kyowa Hakko Kirin Co Ltd Agent anti tumoral
EP1765791A1 (fr) 2004-07-08 2007-03-28 Boehringer Ingelheim Pharmaceuticals Inc. Dérivés de pyrimidine utiles comme inhibiteurs de la pkc-thêta
WO2006027377A1 (fr) 2004-09-10 2006-03-16 Altana Pharma Ag Combinaison de ciclesonide et d'inhibiteur de syk et procedes d'utilisation
CA2579017A1 (fr) 2004-09-10 2006-03-16 Altana Pharma Ag Inhibiteur de roflumilast et de syk combine et procedes d'utilisation associes
MX2007003796A (es) 2004-09-30 2007-04-25 Tibotec Pharm Ltd Pirimidinas 5-sustituidas inhibidoras del virus de inmunodeficiencia humana.
JP2006124387A (ja) 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
WO2006091737A1 (fr) 2005-02-24 2006-08-31 Kemia, Inc. Modulateurs de l'activite de gsk-3
JP2009544592A (ja) 2006-07-21 2009-12-17 ノバルティス アクチエンゲゼルシャフト Ｊａｋキナーゼ阻害剤としての２，４−ジ（アリールアミノ）−ピリミジン−５−カルボキサミド化合物
US20080139531A1 (en) 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
UA97834C2 (ru) 2007-04-18 2012-03-26 Пфайзер Продактс Инк. Производные сульфониламида для лечения анормального роста клеток
JP2010525047A (ja) 2007-04-27 2010-07-22 アストラゼネカ アクチボラグ 増殖状態の処置のためのＥｐｈＢ４キナーゼ阻害剤としてのＮ’−（フェニル）−Ｎ−（モルホリン−４−イル−ピリジン−２−イル）−ピリミジン−２，４−ジアミン誘導体
CN101796046A (zh) 2007-07-16 2010-08-04 阿斯利康(瑞典)有限公司 嘧啶衍生物934
WO2009012421A1 (fr) 2007-07-17 2009-01-22 Rigel Pharmaceuticals, Inc. Pyrimidinediamines substituées par des amines cycliques utilisées en tant qu'inhibiteurs de la pkc
SG2014015085A (en) 2008-04-16 2014-06-27 Portola Pharm Inc 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
JP5705720B2 (ja) 2008-04-16 2015-04-22 ポートラ ファーマシューティカルズ， インコーポレイテッド Ｓｙｋまたはｊａｋキナーゼ阻害剤としての２，６−ジアミノ−ピリミジン−５−イル−カルボキサミド
JP2011518219A (ja) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
SI2300013T1 (en) 2008-05-21 2018-03-30 Adriad Pharmacaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
UY31929A (es) 2008-06-25 2010-01-05 Irm Llc Compuestos y composiciones como inhibidores de cinasa
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CA2986640C (fr) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Composes hetero-aryles et leurs utilisations
EP2325175A4 (fr) 2008-09-01 2012-03-21 Astellas Pharma Inc Composé 2,4-diaminopyrimidine
CN102159547A (zh) 2008-09-18 2011-08-17 安斯泰来制药株式会社 杂环甲酰胺化合物
TW201016676A (en) 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
ES2634445T3 (es) 2008-10-31 2017-09-27 Janssen Biotech, Inc. Diferenciación de las células madre embrionarias humanas con el linaje endocrino pancreático
WO2010068863A2 (fr) * 2008-12-12 2010-06-17 Cystic Fibrosis Foundation Therapeutics, Inc. Composés de pyrimidine et leurs procédés de fabrication et d'utilisation
EP2375899B1 (fr) 2009-01-12 2015-02-25 Array Biopharma Inc. Composés contenant de la pipéridine et leur utilisation dans le traitement du diabète
JP2012515148A (ja) 2009-01-13 2012-07-05 グラクソ グループ リミテッド Ｓｙｋキナーゼ阻害剤としてのピリミジンカルボキサミド誘導体
ES2635504T3 (es) 2009-01-21 2017-10-04 Rigel Pharmaceuticals, Inc. Derivados de N2-(3-piridilo o fenil)-N4-(4-piperidil)-2,4-pirimidinadiamina útiles en el tratamiento de enfermedades inflamatorias, toimmunitarias o proliferativas
AR076550A1 (es) 2009-05-06 2011-06-22 Portola Pharm Inc Inhibidores de la janus tirosina kinasa (jak)
MX2011011875A (es) 2009-05-08 2011-12-08 Astellas Pharma Inc Compuesto de carboxamida heterociclica diamino.
MX2011013325A (es) 2009-06-10 2012-04-30 Abbott Lab 2-(lh-pirazol-4-ilamino)-pirimidina como inhibidores de cinasa.
JP2012197231A (ja) 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
EP2480549B1 (fr) 2009-09-24 2015-04-08 Fundación Centro Nacional De Investigaciones Oncológicas Carlos III Imidazo[3,2-d]pyrazines fusionnees utilisees comme inhibiteurs de kinase PI3
WO2011065800A2 (fr) 2009-11-30 2011-06-03 주식회사 오스코텍 Dérivé de pyrimidine, procédé de préparation de ce dérivé et composition pharmaceutique contenant ce dérivé
WO2011068898A1 (fr) 2009-12-01 2011-06-09 Rigel Pharmaceuticals, Inc. Inhibiteurs de la protéine kinase c et leurs utilisations
EP2595982B1 (fr) 2010-07-21 2018-06-13 Rigel Pharmaceuticals, Inc. Inhibiteurs de protéine kinase c et leurs utilisations
US8580805B2 (en) 2010-08-31 2013-11-12 Hubert Maehr Pyrimidine carboxamide derivatives
US20130244963A1 (en) 2010-09-30 2013-09-19 Portola Pharmaceuticals, Inc. Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
US20130252917A1 (en) 2010-09-30 2013-09-26 Portola Pharmaceuticals, Inc. Combination therapy of 4-(3-(2h-1,2,3-triazo-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide and fludarabine
CN105001165B (zh) 2011-04-22 2020-06-23 西格诺药品有限公司 取代的二氨基嘧啶其组合物，和用其治疗的方法
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
JP6903577B2 (ja) 2014-12-16 2021-07-14 シグナル ファーマシューティカルズ，エルエルシー 皮膚におけるｃ−Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法
CA3210612A1 (fr) * 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Formulations de 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide

Also Published As

Publication number Publication date
CA2970926A1 (fr) 2016-06-23
EP3712134A1 (fr) 2020-09-23
AU2020203497B2 (en) 2022-03-03
NZ732793A (en) 2023-07-28
US20180009765A1 (en) 2018-01-11
US10131639B2 (en) 2018-11-20
EA201791327A1 (ru) 2018-03-30
CA2970926C (fr) 2023-10-24
ES2877642T3 (es) 2021-11-17
IL252900A0 (en) 2017-08-31
SA517381749B1 (ar) 2021-12-04
CL2017001545A1 (es) 2018-02-09
SG11201704827UA (en) 2017-07-28
US20190031619A1 (en) 2019-01-31
US9796685B2 (en) 2017-10-24
AU2020203497A1 (en) 2020-06-18
CN112451502B (zh) 2023-10-27
EA033530B1 (ru) 2019-10-31
US10590089B2 (en) 2020-03-17
JP2017537954A (ja) 2017-12-21
JP2020158510A (ja) 2020-10-01
US20160168105A1 (en) 2016-06-16
CN107108524A (zh) 2017-08-29
EP3233809A4 (fr) 2018-05-30
JP6762940B2 (ja) 2020-09-30
CN112451502A (zh) 2021-03-09
CA3210612A1 (fr) 2016-06-23
EP3233809A1 (fr) 2017-10-25
JP7022172B2 (ja) 2022-02-17
AU2015362728A1 (en) 2017-07-13
AU2015362728B2 (en) 2020-06-25
MX2021005207A (es) 2021-07-15
EP3712134B1 (fr) 2023-11-29
ES2972295T3 (es) 2024-06-12
SG10202010389TA (en) 2020-11-27
ECSP17038150A (es) 2017-07-31
BR112017012795A2 (pt) 2018-01-02
WO2016100310A1 (fr) 2016-06-23
KR102606253B1 (ko) 2023-11-27
KR20170097037A (ko) 2017-08-25
CO2017006087A2 (es) 2017-10-20
EP3233809B1 (fr) 2021-04-21
MX2017007883A (es) 2017-09-05

Similar Documents

Publication Publication Date Title
IL252900A0 (en) Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
IL275305A (en) Solid forms of 2– (tert-butylamino) –4 - ((1R, 3R, 4R) –3– hydroxy-4 – methylcyclohexylamino) –pyrimidine – 5 – carboxamide, their compositions and methods of use
EP3250557A4 (fr) Isotopologues de 2-(tert-butylamino)-4-((1r,3r,4r) -3-hydroxy-4-méthylcyclohexylamino)-pyrimidine-5-carboxamide
ZA201701637B (en) Eutectic formulations of cyclobenzaprine hydrochloride
IL270885A (en) Compounds for the treatment of post-traumatic stress disorder
PT3348260T (pt) Composição farmacêutica de tramadol para utilização oftálmica
SG11201707117SA (en) Ophthalmic composition
ZA201801496B (en) Vlp stabilized vaccine compositions
EP3265177C0 (fr) Préparations de composés hydrophiles
PT3142641T (pt) Formulações para o tratamento de hipertiroidismo
EP3368517C0 (fr) Composés, compositions et procédés de lutte contre les biofilms
EP3349853A4 (fr) Promédicaments de fencamfamine
EP3290049A4 (fr) Composition vaccinale contre les allergies
HK1258765A1 (zh) 治療性化合物、組合物和它們的使用方法
EP3212611A4 (fr) Formes cristallines de chlorhydrate de vérapamil
LT3389638T (lt) Farmacinė kompozicija, kurios sudėtyje yra pimobendano
ZA201704927B (en) Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide,compositions thereof and methods of their use
GB201402377D0 (en) Stable polymorph form B of tapentadol hydrochloride
GB201611619D0 (en) Novel formulations of losartan
GB201611623D0 (en) Novel formulations of losartan
GB201512635D0 (en) Uses of therapeutic compounds
GB201504482D0 (en) Novel formulations